Key result
Obesity in PCOS is linked to ~70% higher HOMA-IR versus non-obese patients.
Why the study?
Insulin resistance and plasma levels of visfatin and resistin in obese and non-obese PCOS patients were evaluated to understand metabolic differences.
Are insulin resistance and plasma levels of visfatin and resistin different between obese and non-obese patients with polycystic ovary syndrome compared to healthy controls?
Observational (n=55)
Are insulin resistance and plasma levels of visfatin and resistin different between obese and non-obese patients with polycystic ovary syndrome compared to healthy controls?
Absolute Event Rate: 3.4% vs 2%
p-value: p=<0.01
Obese patients with PCOS have significantly higher insulin resistance compared to non-obese PCOS patients and healthy controls, but plasma visfatin and resistin levels do not differ significantly.
Supports obesity-stratified IR assessment in PCOS; leaves open visfatin/resistin roles and requires prospective validation.
This study was designed to evaluate insulin resistance and plasma levels of visfatin and resistin in obese and non-obese patients with polycystic ovary syndrome (PCOS). A total of 37 premenopausal PCOS patients with (n = 18, mean (SD) age: 27.5 (5.7 years) or without obesity (n = 19, mean (SD) age: 23.7 (3.1) years) and healthy volunteers (n = 18, mean (SD) age:29.8 (4.1) years) were included in this study. Data on clinical characteristics, glycemic parameters and lipid parameters were recorded for each subject as were plasma visfatin and resistin levels. Mean (SD) HOMA-IR values were significantly higher in obese PCOS patients (3.4 (1.7)) compared with non-obese PCOS patients (2.0 (1.2), p<0.01) and controls (1.6 (0.8), p<0.01). No significant difference was noted between study groups in terms of plasma resistin (ng/mL) or visfatin (ng/mL) levels. There was no correlation between serum plasma visfatin (r = 0.127, p = 0.407) and resistin (r = -0.096, p = 0.544) levels and HOMA-IR. In conclusion, our findings revealed increased likelihood of metabolic and dyslipidemic manifestations in obese compared to non-obese PCOS patients, while no significant difference was noted in visfatin and resistin levels among PCOS patients in terms of co-morbid obesity and in comparison to controls.
No takes yet. Share an insight, caveat, or question.
Gül et al. (2015) conducted an observational in Polycystic ovary syndrome (n=55). Obesity vs. Non-obese PCOS and healthy volunteers was evaluated on HOMA-IR values (p=<0.01). Obese patients with PCOS had significantly higher HOMA-IR values compared to non-obese PCOS patients (3.4 vs 2.0, p<0.01), with no significant differences in plasma visfatin or resistin levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: